JP2003532626A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003532626A5 JP2003532626A5 JP2001517507A JP2001517507A JP2003532626A5 JP 2003532626 A5 JP2003532626 A5 JP 2003532626A5 JP 2001517507 A JP2001517507 A JP 2001517507A JP 2001517507 A JP2001517507 A JP 2001517507A JP 2003532626 A5 JP2003532626 A5 JP 2003532626A5
- Authority
- JP
- Japan
- Prior art keywords
- embedded image
- disease
- pharmaceutical composition
- composition according
- represented
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 description 14
- 150000001875 compounds Chemical class 0.000 description 10
- 201000010099 disease Diseases 0.000 description 7
- 125000003545 alkoxy group Chemical group 0.000 description 6
- 125000000217 alkyl group Chemical group 0.000 description 6
- 125000003710 aryl alkyl group Chemical group 0.000 description 6
- 125000003118 aryl group Chemical group 0.000 description 6
- 206010053643 Neurodegenerative disease Diseases 0.000 description 4
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 4
- 125000001118 alkylidene group Chemical group 0.000 description 4
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 4
- 125000000753 cycloalkyl group Chemical group 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 125000004435 hydrogen atoms Chemical class [H]* 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 0 C*(*)S(NC)(=O)=O Chemical compound C*(*)S(NC)(=O)=O 0.000 description 2
- 210000003169 Central Nervous System Anatomy 0.000 description 2
- 206010022114 Injury Diseases 0.000 description 2
- 210000001428 Peripheral Nervous System Anatomy 0.000 description 2
- 125000005083 alkoxyalkoxy group Chemical group 0.000 description 2
- 125000000033 alkoxyamino group Chemical group 0.000 description 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 2
- 125000002431 aminoalkoxy group Chemical group 0.000 description 2
- 125000001691 aryl alkyl amino group Chemical group 0.000 description 2
- 125000002102 aryl alkyloxo group Chemical group 0.000 description 2
- 125000001769 aryl amino group Chemical group 0.000 description 2
- 125000005160 aryl oxy alkyl group Chemical group 0.000 description 2
- 125000004104 aryloxy group Chemical group 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 125000000000 cycloalkoxy group Chemical group 0.000 description 2
- 125000006310 cycloalkyl amino group Chemical group 0.000 description 2
- 125000005112 cycloalkylalkoxy group Chemical group 0.000 description 2
- 201000004624 dermatitis Diseases 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 125000005842 heteroatoms Chemical group 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- 206010001897 Alzheimer's disease Diseases 0.000 description 1
- 206010002026 Amyotrophic lateral sclerosis Diseases 0.000 description 1
- 206010002556 Ankylosing spondylitis Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 208000006673 Asthma Diseases 0.000 description 1
- 210000004556 Brain Anatomy 0.000 description 1
- 206010006451 Bronchitis Diseases 0.000 description 1
- 206010009887 Colitis Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 206010011401 Crohn's disease Diseases 0.000 description 1
- 208000005679 Eczema Diseases 0.000 description 1
- 206010015037 Epilepsy Diseases 0.000 description 1
- 208000006881 Esophagitis Diseases 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 210000002216 Heart Anatomy 0.000 description 1
- 208000006454 Hepatitis Diseases 0.000 description 1
- 201000001971 Huntington's disease Diseases 0.000 description 1
- 206010021972 Inflammatory bowel disease Diseases 0.000 description 1
- 208000002551 Irritable Bowel Syndrome Diseases 0.000 description 1
- 210000003734 Kidney Anatomy 0.000 description 1
- 208000007177 Left Ventricular Hypertrophy Diseases 0.000 description 1
- 210000004185 Liver Anatomy 0.000 description 1
- 208000010125 Myocardial Infarction Diseases 0.000 description 1
- 206010030216 Oesophagitis Diseases 0.000 description 1
- 206010061536 Parkinson's disease Diseases 0.000 description 1
- 208000001293 Peripheral Nervous System Disease Diseases 0.000 description 1
- 206010039073 Rheumatoid arthritis Diseases 0.000 description 1
- 208000008513 Spinal Cord Injury Diseases 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 206010068760 Ulcers Diseases 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 201000001320 atherosclerosis Diseases 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 201000003883 cystic fibrosis Diseases 0.000 description 1
- 231100000406 dermatitis Toxicity 0.000 description 1
- 231100001003 eczema Toxicity 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 201000005569 gout Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000302 ischemic Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 201000004681 psoriasis Diseases 0.000 description 1
- 200000000008 restenosis Diseases 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 201000006704 ulcerative colitis Diseases 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37823499A | 1999-08-19 | 1999-08-19 | |
| US09/378,234 | 1999-08-19 | ||
| US09/642,557 | 2000-08-16 | ||
| US09/642,557 US7119114B1 (en) | 1999-08-19 | 2000-08-18 | Pyrazoloanthrone and derivatives thereof as JNK inhibitors and compositions and methods related thereto |
| PCT/US2000/022727 WO2001012609A1 (en) | 1999-08-19 | 2000-08-19 | Pyrazoloanthrone and derivatives thereof as jnk inhibitors and their compositions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003532626A JP2003532626A (ja) | 2003-11-05 |
| JP2003532626A5 true JP2003532626A5 (zh) | 2007-05-24 |
Family
ID=23492297
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001517507A Pending JP2003532626A (ja) | 1999-08-19 | 2000-08-19 | Ｊｎｋ阻害剤としてのピラゾロアントロン及びその誘導体並びにそれらの組成物 |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP1218347A1 (zh) |
| JP (1) | JP2003532626A (zh) |
| KR (2) | KR20080028516A (zh) |
| CN (1) | CN1304375C (zh) |
| AU (1) | AU780306B2 (zh) |
| CA (1) | CA2383268A1 (zh) |
| HK (1) | HK1053107A1 (zh) |
| NZ (1) | NZ517578A (zh) |
| WO (1) | WO2001012609A1 (zh) |
| ZA (1) | ZA200201312B (zh) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7119114B1 (en) | 1999-08-19 | 2006-10-10 | Signal Pharmaceuticals, Llc | Pyrazoloanthrone and derivatives thereof as JNK inhibitors and compositions and methods related thereto |
| US20040072888A1 (en) * | 1999-08-19 | 2004-04-15 | Bennett Brydon L. | Methods for treating inflammatory conditions or inhibiting JNK |
| US7429599B2 (en) * | 2000-12-06 | 2008-09-30 | Signal Pharmaceuticals, Llc | Methods for treating or preventing an inflammatory or metabolic condition or inhibiting JNK |
| GB0108770D0 (en) | 2001-04-06 | 2001-05-30 | Eisai London Res Lab Ltd | Inhibitors |
| CN1300116C (zh) | 2001-04-16 | 2007-02-14 | 卫材株式会社 | 1h－吲唑化合物 |
| AR035971A1 (es) | 2001-05-16 | 2004-07-28 | Cephalon Inc | Metodos para el tratamiento y la prevencion del dolor |
| CA2452259A1 (en) | 2001-07-23 | 2003-02-06 | Applied Research Systems Ars Holding N.V. | Arylsulfonamide derivatives as c-jun-n-terminal kinases (jnk's) inhibitors |
| DE60332215D1 (de) | 2002-02-28 | 2010-06-02 | Eisai R&D Man Co Ltd | Neue indazolverbindungen mit kondensiertem ring |
| CN100368411C (zh) | 2002-03-28 | 2008-02-13 | 卫材R&D管理有限公司 | 作为c-Jun N-末端激酶抑制剂用于治疗神经变性疾病的7-氮杂吲哚类化合物 |
| AU2003214414B2 (en) | 2002-03-28 | 2008-10-09 | Eisai R & D Management Co., Ltd. | Azaindoles as inhibitors of c-Jun N-terminal kinases |
| NZ536278A (en) * | 2002-04-05 | 2007-05-31 | Boehringer Ingelheim Pharma | p38 kinase inhibitors for treating mucus hypersecretion associated with cystic fibrosis |
| US20040028660A1 (en) * | 2002-05-30 | 2004-02-12 | Anthrogenesis Corporation | Methods of using JNK or MKK inhibitors to modulate cell differentiation and to treat myeloproliferative disorders and myelodysplastic syndromes |
| EP1510516A4 (en) | 2002-05-31 | 2005-11-02 | Eisai Co Ltd | PYRAZOL COMPOUND AND MEDICAL COMPOSITION CONTAINING THEM |
| US20040087642A1 (en) * | 2002-10-24 | 2004-05-06 | Zeldis Jerome B. | Methods of using and compositions comprising a JNK inhibitor for the treatment, prevention, management and/or modification of pain |
| US20040092568A1 (en) * | 2002-10-31 | 2004-05-13 | Zeldis Jerome B. | Methods for the treatment, prevention and management of macular degeneration |
| US20050019366A1 (en) * | 2002-12-31 | 2005-01-27 | Zeldis Jerome B. | Drug-coated stents and methods of use therefor |
| GB0305142D0 (en) | 2003-03-06 | 2003-04-09 | Eisai London Res Lab Ltd | Synthesis |
| WO2004101565A2 (en) | 2003-05-16 | 2004-11-25 | Eisai Co., Ltd. | Jnk inhibitors |
| WO2005046594A2 (en) * | 2003-11-06 | 2005-05-26 | Celgene Corporation | Methods of using and compositions comprising a jnk inhibitor for the treatment and management of asbestos-related diseases and disorders |
| WO2005074921A1 (en) * | 2004-02-09 | 2005-08-18 | University Of Zurich | Treatment of atherosclerosis |
| MX2007001155A (es) * | 2004-07-29 | 2007-08-14 | Creabilis Therapeutics Spa | Uso de inhibidores de k-252a y de quinasa para la prevencion o el tratamiento de patologias asociadas con hmgb1. |
| US7803824B2 (en) | 2004-10-29 | 2010-09-28 | Alcon, Inc. | Use of inhibitors of Jun N-terminal kinases to treat glaucoma |
| US20060094753A1 (en) | 2004-10-29 | 2006-05-04 | Alcon, Inc. | Use of inhibitors of Jun N-terminal kinases for the treatment of glaucomatous retinopathy and ocular diseases |
| JP2008520730A (ja) * | 2004-11-23 | 2008-06-19 | セルジーン・コーポレーション | 中枢神経系傷害の治療用ｊｎｋ阻害剤 |
| US20060223807A1 (en) | 2005-03-29 | 2006-10-05 | University Of Massachusetts Medical School, A Massachusetts Corporation | Therapeutic methods for type I diabetes |
| KR20080044836A (ko) | 2005-07-15 | 2008-05-21 | 라보라뚜와르 세로노 에스. 에이. | 자궁내막증 치료용 ｊｎｋ 억제제 |
| BRPI0613042A2 (pt) | 2005-07-15 | 2010-12-14 | Serono Lab | inibidores de jnk para o tratamento de endometriose |
| GB0516156D0 (en) | 2005-08-05 | 2005-09-14 | Eisai London Res Lab Ltd | JNK inhibitors |
| CN101374941A (zh) | 2005-12-29 | 2009-02-25 | 人类起源公司 | 采集和保存胎盘干细胞的改良组合物及其使用方法 |
| KR102484810B1 (ko) | 2016-05-25 | 2023-01-05 | (주)아모레퍼시픽 | 피부 미백용 조성물 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH538527A (de) * | 1968-11-07 | 1973-06-30 | Hoechst Ag | Verfahren zur Herstellung von faserreaktiven Farbstoffen |
| DE2200127A1 (de) * | 1972-01-03 | 1973-07-12 | Basf Ag | Verfahren zur herstellung von dichlor1,1'-dianthrachinonylen und deren derivaten |
| DE2558813C2 (de) * | 1975-12-27 | 1984-10-31 | Hoechst Ag, 6230 Frankfurt | Lichtempfindliches Gemisch mit synergistischem Initiatorsystem |
| US4198518A (en) * | 1977-09-02 | 1980-04-15 | Ciba-Geigy Corporation | Process for the production of 3-substituted pyrazolanthrones |
-
2000
- 2000-08-19 CA CA002383268A patent/CA2383268A1/en not_active Abandoned
- 2000-08-19 AU AU67863/00A patent/AU780306B2/en not_active Ceased
- 2000-08-19 JP JP2001517507A patent/JP2003532626A/ja active Pending
- 2000-08-19 EP EP00955709A patent/EP1218347A1/en not_active Withdrawn
- 2000-08-19 KR KR1020087006016A patent/KR20080028516A/ko not_active Application Discontinuation
- 2000-08-19 WO PCT/US2000/022727 patent/WO2001012609A1/en active IP Right Grant
- 2000-08-19 CN CNB008143870A patent/CN1304375C/zh not_active Expired - Fee Related
- 2000-08-19 KR KR1020027002168A patent/KR100835700B1/ko not_active IP Right Cessation
- 2000-08-19 NZ NZ517578A patent/NZ517578A/en unknown
-
2002
- 2002-02-15 ZA ZA200201312A patent/ZA200201312B/en unknown
- 2002-12-23 HK HK02109283.5A patent/HK1053107A1/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003532626A5 (zh) | ||
| RU98123074A (ru) | Хинолиновые карбоксамиды в качестве ингибиторов фно и фдэ-iv | |
| RU98123097A (ru) | Карбоксамиды бензофурана и их терапевтическое применение | |
| JP2018519323A5 (zh) | ||
| NO20060911L (no) | Heteroaryl-terahydropiperidylforbindelser nyttige for behandling eller forebygging av smerte | |
| CA2595182A1 (en) | Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith | |
| CH653993A5 (de) | Zwischenprodukte, die zur herstellung von neuen 3-amino-beta-lactam-1-sulfonsaeuren und ihren salzen verwendbar sind. | |
| JP2003534325A5 (zh) | ||
| JP2008526989A5 (zh) | ||
| WO2007051081B1 (en) | Methods and compounds for preparing cc-1065 analogs | |
| JP2012532112A5 (zh) | ||
| JP2002534519A5 (zh) | ||
| RU2001122339A (ru) | Замещенные 2-арил-3-(гетероарил) имидазо [1,2-а] пиримидины, содержащие их фармацевтические композиции и связанные с ними способы | |
| US9156789B2 (en) | Process for sorafenib tosylate polymorph III | |
| JP2008509987A5 (zh) | ||
| RS50918B (sr) | Novi estri fluorenkarbonske kiseline, postupak za njihovo pripremanje, kao i njihova upotreba kao lekova | |
| JP2012524084A5 (zh) | ||
| JP2017508733A5 (zh) | ||
| JP2003503505A5 (zh) | ||
| JP2004520423A5 (zh) | ||
| JP2003511372A5 (zh) | ||
| CA2409842A1 (en) | 1,4-diazepan-2,5-dione derivatives and their use as nk-1 receptor antagonists | |
| JP2014530831A5 (zh) | ||
| CA2645154A1 (en) | Method for producing aminoacetylpyrrolidinecarbonitrile derivative and production intermediate thereof | |
| CA2172162A1 (en) | Optically active imidazolidinone derivative and process for producing the same |